SCHEDULE: General Atlantic Plans Centessa Pharmaceuticals Share Sale

General Atlantic entities have filed an amended Schedule 13D, disclosing a plan to sell up to 3.5 million Centessa Pharmaceuticals ADSs.

Summary

• General Atlantic Cooperatief U.A. and related entities (the "Reporting Persons") beneficially own 9,681,818 ordinary shares of Centessa Pharmaceuticals plc, representing approximately 6.6% of the company's outstanding shares.
• The beneficial ownership percentage is calculated based on 147,793,242 ordinary shares outstanding, which includes 13,372,093 shares issued in a public offering around November 14, 2025.
• On November 17, 2025, General Atlantic UM B.V. (a Reporting Person) entered into a 10b5-1 trading plan with BTIG, LLC.
• Under this plan, up to 3,500,000 American Depositary Shares (ADSs) of Centessa Pharmaceuticals plc may be sold.
• The 10b5-1 plan will terminate on December 17, 2026, or earlier if the 3,500,000 ADSs are sold, or if the plan is otherwise terminated.
• The Reporting Persons have shared voting and dispositive power over the 9,681,818 ordinary shares.
• The filing is an Amendment No. 1 to the original Schedule 13D filed on June 11, 2021.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the 10b5-1 plan provides an orderly exit, the planned disposition of a significant stake by a major investor could be perceived as a negative signal for the company's stock, potentially leading to downward pressure. However, it's a planned, structured exit, not an urgent or distressed sale.

Positives

• The establishment of a 10b5-1 plan provides an orderly and pre-arranged mechanism for the disposition of shares, potentially reducing market impact compared to unplanned sales.

Negatives

• The planned sale of up to 3,500,000 ADSs by a significant shareholder could exert downward pressure on Centessa Pharmaceuticals plc's share price due to increased supply.
• A large institutional investor reducing its stake may be perceived negatively by the market, potentially signaling a lack of conviction in the company's long-term prospects.

Risks

• The disposition of a significant number of shares by a major investor could lead to increased volatility in the issuer's stock price.
• The market's perception of a large shareholder reducing its stake might negatively influence investor sentiment towards Centessa Pharmaceuticals plc.

Future Outlook

General Atlantic UM B.V. intends to sell up to 3,500,000 Centessa Pharmaceuticals ADSs through a pre-arranged 10b5-1 trading plan, which is set to conclude by December 17, 2026, or earlier upon completion of the sales.

Industry Context

This filing reflects a planned reduction in a significant institutional investor's stake in a biotechnology company. Such dispositions are common in the lifecycle of private equity investments in public companies, often occurring after a lock-up period or when an investment thesis matures. It does not inherently reflect broader industry trends but rather a specific portfolio management decision.

Stakeholder Impact

• Shareholders: Potential for increased selling pressure on Centessa Pharmaceuticals plc's stock due to the planned disposition of a significant block of shares.
• Investors: May interpret the sale by a major institutional investor as a signal regarding the company's future prospects, potentially influencing investment decisions.

Next Steps

• Execution of the 10b5-1 trading plan by BTIG, LLC to sell up to 3,500,000 ADSs.
• Termination of the 10b5-1 plan by December 17, 2026, or earlier.

Key Dates

Recommendation

The filing indicates a significant institutional investor, General Atlantic, plans to reduce its stake in Centessa Pharmaceuticals plc through a 10b5-1 plan to sell up to 3.5 million ADSs. While this disposition could create near-term selling pressure on the stock, it is a pre-arranged, orderly exit strategy rather than an immediate, distressed sale. The underlying fundamentals of Centessa Pharmaceuticals plc are not addressed in this filing. Therefore, a 'hold' recommendation is appropriate, advising investors to monitor the execution of the plan and assess its impact on market sentiment and the company's valuation, without suggesting immediate buying or selling based solely on this ownership change.

Keywords

Centessa Pharmaceuticals, General Atlantic, Schedule 13D/A, 10b5-1 Plan, Share Disposition, Institutional Ownership, Biotechnology, Pharmaceuticals, SEC Filing, CNTA